As of June 21, 2025, Xenon Pharmaceuticals Inc (XENE) reports a Net Margin of -1329.48%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Xenon Pharmaceuticals Inc's Net Margin
Over recent years, Xenon Pharmaceuticals Inc's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -1329.48% |
| 2023-12-31 | -1329.48% |
| 2022-12-31 | -427.77% |
| 2021-12-31 | -89.65% |
| 2020-12-31 | -609.08% |
This slight downward trend highlights how Xenon Pharmaceuticals Inc manages its overall profitability and cost control over time.
Comparing Xenon Pharmaceuticals Inc's Net Margin to Peers
To better understand Xenon Pharmaceuticals Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Xenon Pharmaceuticals Inc (XENE) | -1329.48% |
| Aptose Biosciences Inc (APS.TO) | 4175.00% |
| Catalyst Pharmaceuticals Inc (CPRX) | 33.33% |
| MEI Pharma Inc (MEIP) | 27.23% |
| MannKind Corp (MNKD) | 9.66% |
| Theratechnologies Inc (TH.TO) | -9.67% |
Compared to its competitors, Xenon Pharmaceuticals Inc's Net Margin is about average compared to peers, reflecting typical industry profitability.